A Team of Specialists

 
 

The Team

Our regulatory team (of 7) brings over 100 combined years of industry and consulting experience in orphan drug regulations and development. Made up entirely of Ph.D./MS-level, senior regulatory strategists and mechanics, and all the passion in the world, they lead programs to success. Our core team backed by a nonclinical development expert (Ph.D., DABT), clinical pharmacologist (Ph.D.), pharmacometrician (Ph.D.), ex-EMA Reviewer (Ph.D.), and a publisher, offers success time and time again.

“We have gone to great lengths and continue our efforts to bring senior talent together so we can serve our purpose. That coupled with an ideal client experience, ultimately keeps the team unified and consistent, and the client coming back.” ~ Chris


The Client

Our Clients are those looking for strategic and operational support; someone who can be eyes-on and hands-on their program as and when needed; someone to help them navigate this complex regulatory pathway, and help them to decide when and how to submit their orphan drug designations, applications for expedited programs, and interact with the Agencies. They hire us to incorporate data from the smallest of populations coupled with novel therapies into the purest blend of science, regulations, patient care, and corporate objectives. We help them to maneuver the product through the regulatory framework, steering the data into a regulatory position that is poised to accelerate into marketing as early as possible. They trust our team, as we continue to work fast and hard to ensure their success.


The Founders

Over the past two and a half years under the leadership of Co-founders Sabrina Mogle and Chris Novashinski, RareMoon has supported more than 25 Sponsors, successfully lead over 50 projects to completion, and worked on over 34 unique programs.

Sabrina has a total of 14 years of industry experience (the latter four focusing exclusively on orphan drugs), managing over 50 nonclinical and regulatory projects for small biotech and pharma partners, and initially trained under the ex-Director of the Office of Orphan Products, Dr. Tim Cote. She has a comprehension of the unique nature of orphan drug regulations, a passion for serving small pharma and biotech companies, and a thorough understanding of their challenges and needs. Sabrina has a B.S in Molecular Biology from the University of Pittsburgh and has held Corporate Development and Business Development Management and Director roles before forming RareMoon.

Chris brings over 20 years of experience in international business, global team building, executive management, and project management experience to RareMoon. Having played key roles in two fortune 500 companies in start-up phase, Chris brings the direct experience and ability needed to build a company, and drive a team combined with in-house experts and global collaborators, to success. He believes dedicated approach to team building and project management results in an environment where everyone shares in the success and progress and provide's a platform that allows the experts to focus on what is essential - seeing therapies through the regulatory framework that are intended to change the lives of people.


Truth in Numbers

With a 100% success rate, RareMoon is the leading US-based rare disease regulatory service firm. With nearly 100 years of combined experience, our team of experts specialize in both the EMA and FDA orphan regulations.
100%

Success Rate

69

US & EU ODDs

6

Breakthrough Designations

28+

Agency Meetings

10+

PIPs


Testimonials

Innovative Approaches


I am very impressed with RMC’s high quality and innovative approaches on regulatory strategies and their commitment to drug development for rare and orphan diseases. Thank you very much for the excellent results through our collaborations and it has been a great pleasure to work with the RMC team. - SKS

Mission-Focused


The RareMoon team brings exemplary regulatory insights, experience and a mission-focused collaborative approach to managing and navigating innovative treatments for rare diseases. - MJA